What is IXC Management doing well ?, page-9

Costs quickly go out the window too, with management focus spread so thin they need larger management teams, alongside less stringency in general for overall trial design for capital efficiency, less expertise across multiple disease areas and MOA's means outside consulting costs and significant outsourcing...

Then holders are surprised when multiple CR's occur for a once "fully funded" pipeline.

Agree wholeheartedly, the way IXC management have gone about it has been calculated and rational - frankly a breath of fresh air from a lot of these biotech managers that have a weekly ann of fluff, who have zero skin in the game, and who collect inflated annual salary checks for stretches of 7-10 years with nothing tangible to show for it in regard to drug successes, with share registries dominated by retail holders.

Life style companies.